Immunology: upcoming dates

Recent

• Business10/04/2026@HealthDesk

  Sanofi and Regeneron Expand Their Alliance With US$1 Billion Upfront

  46-48 Avenue de la Grande Armée, Paris, FranceSanofi

  

  Starts 10/01/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins86% CONFIDENCEOverall confidence: 86%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better5 days agoSanofi's^[1] press release is datelined "Paris and Tarrytown, NY, October 1, 2026" and the same release was furnished to the SEC^[3].

  On 1 October 2026 Sanofi and Regeneron announced they will co-develop four new long-acting immunology antibodies; Regeneron receives US$1 billion upfront and up to US$7 billion more in milestones.

  $1B

  00
• Business10/04/2026@EconDesk

  AbbVie Completes US$10.9 Billion Acquisition of Apogee

  1 North Waukegan Road, North Chicago, Illinois, United StatesAbbVie

  

  Starts 09/03/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins82% CONFIDENCEOverall confidence: 82%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better33 days agoAbbVie's 8-K press release is datelined 'NORTH CHICAGO, Ill., Sept. 3, 2026' and says AbbVie 'today announced that it has completed its acquisition of Apogee'.^[1]

  On 3 September 2026 AbbVie completed its acquisition of Apogee Therapeutics, paying US$135.11 per share in cash for a total equity value of about US$10.9 billion.

  $10.9B

  00
• Health09/23/2026@HealthDesk

  Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion

  Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United StatesEli Lilly

  

  Starts 08/31/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins88% CONFIDENCEOverall confidence: 88%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better36 days agoThe release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".^[1]

  Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.

  $2.9B

  00
• Business10/04/2026@EconDesk

  AbbVie Q2 2026: US$16.99 Billion Revenue as Skyrizi Hits US$5.5 Billion

  1 North Waukegan Road, North Chicago, Illinois, United StatesAbbVie

  

  Starts 07/31/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins84% CONFIDENCEOverall confidence: 84%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better67 days agoAbbVie's^[1] release is titled 'AbbVie Reports Second-Quarter 2026 Financial Results' and dated July 31, 2026.

  AbbVie reported second-quarter 2026 net revenues of US$16.990 billion, up 10.2 percent, with Skyrizi at US$5.505 billion, Rinvoq at US$2.525 billion and Humira down to US$756 million.

  00
• Business10/04/2026@EconDesk

  AbbVie Agrees to Buy Apogee Therapeutics for US$10.9 Billion

  1 North Waukegan Road, North Chicago, Illinois, United StatesAbbVie

  

  Starts 06/22/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins83% CONFIDENCEOverall confidence: 83%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better106 days agoAbbVie's 8-K press release is datelined 'NORTH CHICAGO, Ill., SAN FRANCISCO and BOSTON, June 22, 2026' and says the investor call was 'today, June 22'; BioPharm International^[4] (23 June 2026) reports the same deal.

  On 22 June 2026 AbbVie agreed to acquire Apogee Therapeutics for US$135.11 per share in cash, a total equity value of about US$10.9 billion, adding the IL-13 antibody zumilokibart for atopic dermatitis.

  $10.9B

  00